CA
NZ
UK
AU
IND
US
…
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 213.90M | 101.40M | 106.70M | 46.50M | 21.84M |
| Net income | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M |
| Selling general administrative | 752.70M | 583.30M | 433.30M | 354.06M | 248.93M |
| Gross profit | 1465.50M | 1119.20M | 1035.80M | 780.70M | 446.35M |
| Reconciled depreciation | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M |
| Ebit | 233.40M | 196.90M | 318.90M | 219.15M | 32.87M |
| Ebitda | 249.00M | 207.80M | 327.50M | 226.60M | 36.90M |
| Depreciation and amortization | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M |
| Non operating income net other | -28.00M | 24.70M | -23.50M | 6.22M | 15.48M |
| Operating income | 249.00M | 196.90M | 318.90M | 219.15M | 36.90M |
| Other operating expenses | 1239.70M | 925.70M | 718.40M | 561.50M | 414.35M |
| Interest expense | 7.10M | 25.80M | 32.80M | 32.00M | 30.53M |
| Tax provision | 59.40M | 11.80M | -300.60M | 9.53M | 0.73M |
| Interest income | - | - | - | 25.74M | 15.05M |
| Net interest income | -7.10M | -25.80M | -32.80M | -31.96M | -30.53M |
| Non recurring | - | 105.30M | 164.50M | 154.27M | - |
| Income tax expense | 59.40M | 11.80M | -300.60M | 9.50M | 0.73M |
| Total revenue | 1488.70M | 1133.50M | 1045.90M | 788.10M | 451.24M |
| Total operating expenses | 1216.50M | 911.40M | 708.30M | 554.10M | 409.46M |
| Cost of revenue | 23.20M | 14.30M | 10.10M | 7.40M | 4.89M |
| Total other income expense net | -35.10M | -95.50M | -212.20M | -172.65M | 15.48M |
| Net income from continuing ops | 154.50M | 89.60M | 407.30M | 37.01M | 21.11M |
| Net income applicable to common shares | 154.50M | 89.60M | 407.30M | 37.01M | 21.11M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 3718.70M | 3251.40M | 2368.70M | 2072.50M | 1734.70M |
| Intangible assets | 36.50M | 35.50M | 37.20M | - | - |
| Other current assets | 112.10M | 97.80M | 464.20M | 261.50M | 215.20M |
| Total liab | 1129.00M | 1019.40M | 660.90M | 698.50M | 608.50M |
| Total stockholder equity | 2589.70M | 2232.00M | 1707.80M | 1374.00M | 1126.20M |
| Other current liab | 397.70M | 35.90M | 292.00M | 194.30M | 147.10M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | 29.20M | -157.10M | -406.80M | -635.80M | -725.40M |
| Other liab | - | - | 29.70M | 12.30M | 9.70M |
| Good will | - | 5.80M | - | - | - |
| Other assets | - | - | 330.90M | 319.50M | 674.00M |
| Cash | 233.00M | 251.10M | 262.90M | 340.80M | 801.00M |
| Total current liabilities | 507.70M | 654.80M | 537.70M | 245.80M | 186.50M |
| Current deferred revenue | - | 339.90M | - | - | - |
| Net debt | 222.10M | 177.30M | 169.40M | 99.60M | -388.70M |
| Short term debt | - | 170.10M | 169.40M | 225.00M | 94.00M |
| Short long term debt | - | 170.10M | 169.40M | - | - |
| Short long term debt total | 455.10M | 428.40M | 262.90M | 440.40M | 412.30M |
| Other stockholder equity | 2554.60M | 2382.00M | 2122.40M | 2011.40M | 1849.70M |
| Property plant equipment | - | - | 58.60M | 58.60M | 44.60M |
| Total current assets | 1724.70M | 1607.00M | 1453.50M | 972.80M | 1016.20M |
| Long term investments | 864.30M | 849.40M | 401.50M | 560.70M | 227.10M |
| Net tangible assets | - | - | 1670.60M | 1374.00M | 1126.20M |
| Short term investments | 843.10M | 780.50M | 726.40M | 370.50M | 613.90M |
| Net receivables | 479.10M | 439.30M | 350.00M | 185.50M | 157.10M |
| Long term debt | - | - | - | 335.10M | 317.90M |
| Inventory | 57.40M | 38.30M | 35.10M | 30.50M | 28.00M |
| Accounts payable | 110.00M | 108.90M | 76.30M | 51.50M | 39.40M |
| Accumulated other comprehensive income | 5.80M | 7.00M | -7.90M | -1.70M | 1.80M |
| Common stock total equity | - | - | 0.10M | 0.10M | 0.10M |
| Retained earnings total equity | - | - | -406.80M | -635.80M | -725.40M |
| Non currrent assets other | 15.50M | 49.60M | 25.00M | 4.40M | 6.40M |
| Non current assets total | 1994.00M | 1644.40M | 915.20M | 1099.70M | 718.50M |
| Capital lease obligations | 455.10M | 258.30M | 93.50M | 105.30M | 94.40M |
| Long term debt total | - | - | - | 335.10M | 317.90M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -110.20M | -102.20M | 15.00M | -127.48M | -218.14M |
| Change to liabilities | 114.60M | 56.80M | 26.90M | 53.95M | 24.22M |
| Total cashflows from investing activities | -177.10M | -130.20M | 4.10M | -211.07M | -242.91M |
| Net borrowings | -279.00M | -0.10M | -186.90M | -186.90M | -186.90M |
| Total cash from financing activities | -234.30M | 27.40M | -157.80M | 27.31M | 29.53M |
| Change to operating activities | -17.20M | -9.20M | -23.60M | 21.88M | 2.66M |
| Net income | 154.50M | 89.60M | 407.30M | 37.01M | 21.11M |
| Change in cash | -73.30M | 153.70M | 74.80M | -31.71M | -112.02M |
| Begin period cash flow | 344.00M | 190.30M | 115.50M | 147.19M | 259.21M |
| End period cash flow | 270.70M | 344.00M | 190.30M | 115.48M | 147.19M |
| Total cash from operating activities | 339.40M | 256.50M | 228.50M | 152.05M | 101.36M |
| Issuance of capital stock | - | - | - | 27.31M | 29.53M |
| Depreciation | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M |
| Other cashflows from investing activities | -50.40M | -4.60M | -4.60M | -68.85M | 0.03M |
| Change to inventory | -2.60M | -2.50M | -10.70M | -6.42M | -3.52M |
| Change to account receivables | -162.20M | -28.40M | -30.50M | -69.17M | -25.11M |
| Sale purchase of stock | 44.70M | 27.50M | 29.10M | 27.31M | 29.53M |
| Other cashflows from financing activities | -177.10M | -130.20M | 4.10M | -211.07M | -242.91M |
| Change to netincome | 266.30M | 142.90M | -188.60M | 76.02M | 57.31M |
| Capital expenditures | 16.50M | 23.40M | 10.90M | 14.75M | 24.81M |
| Change receivables | -162.20M | -28.40M | -30.50M | -69.17M | -25.11M |
| Cash flows other operating | -48.00M | -30.10M | -5.90M | 34.87M | 3.01M |
| Cash and cash equivalents changes | -72.00M | 153.70M | 74.80M | -31.71M | -112.02M |
| Change in working capital | -67.40M | 16.70M | -37.90M | 0.24M | -1.76M |
| Stock based compensation | 173.10M | 134.20M | 100.00M | 75.26M | 58.07M |
| Other non cash items | 44.50M | 0.80M | 61.20M | 21.07M | 19.23M |
| Free cash flow | 322.90M | 233.10M | 217.60M | 137.31M | 76.55M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences Inc |
-0.28 0.19% |
146.10 | 41.02 | 23.47 | 4.96 | 4.72 | 4.76 | 20.52 |
| MKKGY Merck KGaA ADR |
-0.01 0.03% |
33.66 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
0.04 0.02% |
169.25 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.90 4.50% |
20.91 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
4.03 10.61% |
42.00 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
12780 El Camino Real, San Diego, CA, United States, 92130
858 617 7600
1800
| Name | Title | Year Born |
|---|---|---|
| Dr. Kevin C. Gorman Ph.D. | CEO & Director | 1958 |
| Mr. Matthew C. Abernethy | Chief Financial Officer | 1980 |
| Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 1964 |
| Mr. Eric S. Benevich | Chief Commercial Officer | 1965 |
| Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1964 |
| Dr. Dimitri E. Grigoriadis | Chief Research Officer | 1958 |
| Jane Sorensen | Head of Investor Relations | NA |
| Mr. Darin M. Lippoldt | Chief Legal Officer & Corp. Sec. | 1966 |
| Mr. Kyle W. Gano | Chief Bus. Devel. and Strategy Officer | 1973 |
| Ms. Julie S. Cooke | Chief HR Officer | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...